AbbVie announced final Phase 3 results from the CLL14 trial showing that a fixed-duration venetoclax plus obinutuzumab treatment significantly improves progression-free survival (PFS) in previously untreated chronic lymphocytic leukemia (CLL) patients compared to chlorambucil plus obinutuzumab. The nine-year data revealed a median PFS of 6.4 years versus 3.2 years and a median time to next treatment of 7.6 years, highlighting durable efficacy and safety. This supports venetoclax-based regimens as a first-line treatment offering patients longer treatment-free periods. The trial enrolled 432 patients with coexisting conditions, confirming the combination's benefit in unfit patients.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
